T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Related Experiment Video
Updated: Apr 1, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Armen Mardiros1, Stephen J Forman, Lihua E Budde
1aKite Pharma, Inc., Santa Monica bDepartment of Hematology & Hematopoietic Cell Transplantation cDepartment of Cancer Immunotherapeutics dDepartment of Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Purpose Of Review:
The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia.
Recent Findings:
CD123 is a leukemia-associated antigen that expresses at high levels in leukemic stem cells and leukemic blasts and low level in normal hematopoietic stem/progenitor cells. Immune-based therapies targeting CD123 are being developed. Preclinical data suggest that CD123 CAR T cells exhibit potent antileukemic activity and various impacts on normal hematopoiesis.
Summary:
CD123 is an attractive surface target for novel antileukemic therapies. CD123 CAR T-cell-based immunotherapy is a promising treatment for patients with relapsed or refractory acute myeloid leukemia.
More Related Videos
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023